Farmas USA

CYTX

Opinión posiva (que no concesión) sobre fármaco huérfano en la UE. Es un poco tendenciosa.

http://www.streetinsider.com/Corporate+News/Cytori+Therapeutics+%28CYTX%29+ECCS-50+Receives+Positive+Orphan+Drug+Status+Opinion+in+Europe/10304100.html?si_client=intbro

¿Alguien sabé qué carajo están soltando en la conferencia de XOMA para que caiga un 7% en pre?????

Creo que sale de OTC en un par de dias. Vamos a ver si la entrada en Nasdaq le sienta bien y podemos aprovecharlo.

 

OCAT

muy poco volumen en pre.

De todos modos, como los datos de fase 3 no se liberan hoy...

XOMA

http://www.xoma.com/documents/2-01-15XOMACorporatePresentation.pdf

XOMA
Previo a apertura del mercado Trading - NASDAQ.com
$3.95* -0.155 -3.78%
Volumen 32,049

Ya no es un -7%

OCAT

Nueva patente de Lanza. Son las células encargadas del sistema inmunológico.

Kimbrel, Erin Anne (Sudbury, MA, US)
Lanza, Robert (Clinton, MA, US)
Chu, Jianlin (Bedford, MA, US)
Kouris, Nicholas Arthur (Hudson, MA, US)
Application Number:
13/691349
Publication Date:
02/24/2015
Filing Date:
11/30/2012

The invention claimed is:

1. A method for generating mesenchymal stromal cells comprising culturing hemangioblasts under conditions that give rise to mesenchymal stromal cells.

2. The method of claim 1, wherein said hemangioblasts are cultured on a matrix.

3. The method of claim 2, wherein said matrix comprises a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells.

4. The method of claim 1, wherein said hemangioblasts are differentiated from pluripotent cells.

5. The method of claim 4, wherein said hemangioblasts are differentiated from pluripotent cells by a method comprising (a) culturing said pluripotent cells to form clusters of cells.

6. The method of claim 5, wherein in step (a), the pluripotent cells are cultured in the presence of vascular endothelial growth factor (VEGF) and/or bone morphogenic protein 4 (BMP-4).

7. The method of claim 5, wherein said hemangioblasts are differentiated from pluripotent cells by a method further comprising: (b) culturing said clusters of cells in the presence of at least one growth factor in an amount sufficient to induce the differentiation of said clusters of cells into hemangioblasts.

8. The method of claim 7, wherein said at least one growth factor added in step (b) comprises one or more of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), bone morphogenic protein 4 (BMP-4), stem cell factor (SCF), Flt 3L (FL), thrombopoietin (TPO), and/or tPTD-HOXB4.

9. The method of claim 7, further comprising (c) dissociating said clusters of cells, optionally into single cells.

10. The method of claim 7, further comprising (d) culturing said hemangioblasts in a medium comprising at least one additional growth factor, wherein said at least one additional growth factor is in an amount sufficient to expand the hemangioblasts.

11. The method of claim 10, wherein in step (d), said at least one additional growth factor comprises one or more of: insulin, transferrin, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), stem cell factor (SCF), vascular endothelial growth factor (VEGF), bone morphogenic protein 4 (BMP-4), and/or tPTD-HOXB4.

12. The method of claim 5, wherein said cells are human.

13. The method of claim 1, wherein said hemangioblasts are plated on a matrix.

14. Mesenchymal stromal cells derived from hemangioblasts obtained by the method of claim 1.

15. The mesenchymal stromal cells of claim 14, wherein (i) at least 50% of said mesenchymal stromal cells are positive for all of CD10, CD24, IL-11, AIRE-1, ANG-1, CXCL1, CD105, CD73, CD90, CD105, CD13, CD29, CD 44, CD166, CD274, and HLA-ABC and (ii) no more than 30% or no more than 10% or no more than 5% of said mesenchymal stromal cells are positive for CD31, CD34, CD45, CD133, FGFR2, CD271, Stro-1, CXCR4 or TLR3.

16. The mesenchymal stromal cells of claim 14, wherein said mesenchymal stromal cells are capable of undergoing at least 5 population doublings in culture.

17. The mesenchymal stromal cells of claim 14, wherein the mesenchymal stromal cells are mitotically inactivated.

18. The mesenchymal stromal cells of claim 17, comprising at least 106 mesenchymal stromal cells and a pharmaceutically acceptable carrier.

19. The composition of claim 14, wherein said mesenchymal stromal cells are able to undergo (a) at least 10 population doublings and wherein the 10 population doublings occur within about 27 days, less than about 26 days, than 25 days, than about 24 days, less than about 23 days, less than about 22 days, or lower; (b) at least 15 population doublings; (c) at least 20, 25, 30, 35, 40, 45, 50 or more population doublings; or (d) at least 15 population doublings, at least 20 population doublings, or at least 25 population doublings in culture.

20. The composition of claim 14, wherein (a) at least 30% of the mesenchymal stromal cells are positive for CD10; (b) at least 60% of the mesenchymal stromal cells are positive for markers CD73, CD90, CD105, CD13, CD29, CD44, CD166 and HLA-ABC; or (c) less than 30% of the mesenchymal stromal cells are positive for markers CD31, CD34, CD45, CD133, FGFR2, CD271, Stro-1, CXCR4 and TLR3.

21. The composition of claim 14, wherein the mesenchymal stromal cells have a potency in an immune regulatory assay that is greater than the potency of bone marrow derived mesenchymal stromal cells.

22. The composition of claim 21, wherein said potency is assayed by an immune regulatory assay that determines an EC50 dose.

Entrada en el Nasdaq el jueves

http://ir.ocata.com/sec-filings/content/0001104659-15-013039/a15-5190_28a12b.htm

Sí, creo que para meterme hoy no tengo coraje tras el boom de ayer.